AcelRx Pharmaceuticals: A Bullish View In 3 Song Titles
Photo by Ja’Crispy/iStock via Getty Images
I have covered AcelRx Pharmaceuticals (ACRX) before, so investors should view this as an update to my previous articles.
Almost exactly a year ago I expected DSUVIA sales to take off, and ACRX being in a position similar to that of a space vessel about to lift. The prediction wasn’t all wrong, in particular 3q20 sales picked up substantially, but COVID-19 related restrictions for medical (and sales) procedures provided stronger headwinds than anticipated.
…
